Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer
{{output}}
Background: S-1, an oral fluoropyrimidine, is usually given for 4 weeks (80 mg/m2/day) followed by a 2-week rest. However, compliance with this regimen is unsatisfactory because of adverse events such as leukopenia, anorexia, and... ...
